Sign in

    Justin Wolf

    Research Analyst at Jones Trading

    No verifiable information is available confirming Justin Wolf as an analyst at Jones Trading. No LinkedIn profile or public record details exist to establish his exact job title, company coverage, performance metrics, career history, or professional credentials in equity research or trading. There is no data indicating coverage of specific companies, tracked returns, industry rankings, or history at Jones Trading or other firms. Without authoritative confirmation, a comprehensive professional profile cannot be provided.

    Justin Wolf's questions to Y-mAbs Therapeutics (YMAB) leadership

    Justin Wolf's questions to Y-mAbs Therapeutics (YMAB) leadership • Q2 2024

    Question

    Justin Wolf from Jones Trading requested more color on the expected timeline for Parts B and C of the SADA clinical study, relative to the progress of Part A.

    Answer

    President and CEO Michael Rossi projected that Part A will conclude later in 2024, with Part B starting in early 2025. He anticipates Part B could potentially be completed in 2025 or early 2026, noting that trial recruitment has accelerated. Chief Medical Officer Dr. Vignesh Rajah added that this timeline is reasonable but remains dependent on the dosimetry results observed along the way.

    Ask Fintool Equity Research AI